Article Sidebar
Published:
May 12, 2021DOI:
10.4314/tjpr.v18i3.5Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of Yugan Sanjie decoction on expressions of regulatory T cells, serum P21 protein and vascular endothelial growth factor in mice with hepatocellular carcinoma
Abstract
Purpose: To investigate the effect of Yugan Sanjie decoction on the expressions of regulatory T cells (Tregs), serum P21 protein and vascular endothelial growth factor (VEGF) in mice with hepatocellular carcinoma.
Methods: A total of forty specific-pathogen-free (SPF) Kunming mice were randomly assigned to four groups of 10 mice each. Except for normal control group, the other three groups were transfected with hepatoma-22 (H22) cells to establish a mouse model of liver cancer. Mice in the cyclophosphamide group was given cyclophosphamide at a dose of 20 mg/kg daily intragastrically, while those in decoction group were treated with Yugan Sanjie decoction (0.4 ml/kg/day) intraperitoneally. After 30 days of treatment, serum levels of CD4+ Th17, CD4+CD25+ Treg, Th17/Treg, TNF-α, and VEGF were determined.
Results: There was lower serum level of CD4+ Th17 in the decoction group than in negative control and cyclophosphamide groups (p < 0.05). However, higher serum levels of CD4+CD25+ Treg and Th17/Treg were seen in the decoction group, relative to the negative control and cyclophosphamide groups (p < 0.05). Serum TNF-α was also markedly elevated in decoction group, when compared with negative control and cyclophosphamide groups (p < 0.05). Serum VEGF was markedly lower in decoction group than in negative control and cyclophosphamide groups, and was appreciably lower in cyclophosphamide group than in negative control group (p < 0.05).
Conclusion: Yugan Sanjie decoction effectively alleviates clinical symptoms of LC, and improves immune function of mice by regulating serum levels of T lymphocytes. These findings provide scientific support for a new treatment strategy.
